{"aliases":[{"type":"USBrandName","name":"Orserdu"},{"type":"CASRegistryName","name":"1349723-93-8"},{"type":"Synonym","name":"RAD-1901 dihydrochloride"},{"type":"Synonym","name":"RAD1901 dihydrochloride"}],"definition":{"html":"The hydrochloride salt form of elacestrant, an orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. This prevents ER-mediated signaling and inhibits proliferation of ER-expressing cancer cells.","text":"The hydrochloride salt form of elacestrant, an orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. This prevents ER-mediated signaling and inhibits proliferation of ER-expressing cancer cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/elacestrant-dihydrochloride","text":"Elacestrant Dihydrochloride"},"nciConceptId":"C171898","nciConceptName":"Elacestrant Hydrochloride","termId":768338,"name":"elacestrant hydrochloride","firstLetter":"e","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"elacestrant-hydrochloride"}